AU2020412201B2 - TGF-beta-RII binding proteins - Google Patents

TGF-beta-RII binding proteins

Info

Publication number
AU2020412201B2
AU2020412201B2 AU2020412201A AU2020412201A AU2020412201B2 AU 2020412201 B2 AU2020412201 B2 AU 2020412201B2 AU 2020412201 A AU2020412201 A AU 2020412201A AU 2020412201 A AU2020412201 A AU 2020412201A AU 2020412201 B2 AU2020412201 B2 AU 2020412201B2
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
tgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020412201A
Other languages
English (en)
Other versions
AU2020412201A1 (en
Inventor
Cornelius Adriaan De Kruif
Rinse KLOOSTER
Mark Throsby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merus NV
Original Assignee
Merus NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus NV filed Critical Merus NV
Publication of AU2020412201A1 publication Critical patent/AU2020412201A1/en
Priority to AU2023200779A priority Critical patent/AU2023200779B2/en
Application granted granted Critical
Publication of AU2020412201B2 publication Critical patent/AU2020412201B2/en
Assigned to MERUS B.V. reassignment MERUS B.V. Amend patent request/document other than specification (104) Assignors: MERUS N.V.
Priority to AU2026203599A priority patent/AU2026203599A1/en
Priority to AU2026203807A priority patent/AU2026203807A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020412201A 2019-12-24 2020-12-22 TGF-beta-RII binding proteins Active AU2020412201B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2023200779A AU2023200779B2 (en) 2019-12-24 2023-02-13 TGF-beta-RII binding proteins
AU2026203599A AU2026203599A1 (en) 2019-12-24 2026-05-11 TGF-beta-RII binding proteins
AU2026203807A AU2026203807A1 (en) 2019-12-24 2026-05-18 TGF-beta-RII binding proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2024576 2019-12-24
NL2024576 2019-12-24
PCT/NL2020/050813 WO2021133167A1 (en) 2019-12-24 2020-12-22 Tgf-beta-rii binding proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2023200779A Division AU2023200779B2 (en) 2019-12-24 2023-02-13 TGF-beta-RII binding proteins
AU2026203599A Division AU2026203599A1 (en) 2019-12-24 2026-05-11 TGF-beta-RII binding proteins

Publications (2)

Publication Number Publication Date
AU2020412201A1 AU2020412201A1 (en) 2022-07-14
AU2020412201B2 true AU2020412201B2 (en) 2026-02-12

Family

ID=69700252

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2020412201A Active AU2020412201B2 (en) 2019-12-24 2020-12-22 TGF-beta-RII binding proteins
AU2023200779A Active AU2023200779B2 (en) 2019-12-24 2023-02-13 TGF-beta-RII binding proteins
AU2026203599A Pending AU2026203599A1 (en) 2019-12-24 2026-05-11 TGF-beta-RII binding proteins
AU2026203807A Pending AU2026203807A1 (en) 2019-12-24 2026-05-18 TGF-beta-RII binding proteins

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2023200779A Active AU2023200779B2 (en) 2019-12-24 2023-02-13 TGF-beta-RII binding proteins
AU2026203599A Pending AU2026203599A1 (en) 2019-12-24 2026-05-11 TGF-beta-RII binding proteins
AU2026203807A Pending AU2026203807A1 (en) 2019-12-24 2026-05-18 TGF-beta-RII binding proteins

Country Status (13)

Country Link
US (1) US12570747B2 (enExample)
EP (2) EP4269433A3 (enExample)
JP (3) JP7633259B2 (enExample)
KR (2) KR20220117267A (enExample)
CN (3) CN116199780A (enExample)
AR (2) AR120914A1 (enExample)
AU (4) AU2020412201B2 (enExample)
BR (1) BR112022012522A2 (enExample)
IL (2) IL294181A (enExample)
MX (2) MX2022007919A (enExample)
PH (1) PH12022551527A1 (enExample)
TW (2) TW202128747A (enExample)
WO (1) WO2021133167A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116199780A (zh) 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
MX2024006018A (es) * 2021-11-19 2024-07-29 Merus Nv Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii.
CN120731229A (zh) 2022-12-20 2025-09-30 美勒斯公司 FAP结合域以及结合FAP和TGF-βRII的双特异性结合部分

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1245676A1 (en) * 1999-11-18 2002-10-02 Japan Tobacco Inc. Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof
WO2010053814A1 (en) * 2008-11-07 2010-05-14 Imclone Llc Anti-tgf-beta receptor ii antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
US9150651B2 (en) 2011-01-06 2015-10-06 Glaxo Group Limited Single variable domain immunoglobulins that bind TGF-beta receptor II
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
JP2018527903A (ja) 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Ｇｄｆ１１結合タンパク質およびその使用
TW201825519A (zh) * 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
CA3094318A1 (en) 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
CN116199780A (zh) 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1245676A1 (en) * 1999-11-18 2002-10-02 Japan Tobacco Inc. Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof
WO2010053814A1 (en) * 2008-11-07 2010-05-14 Imclone Llc Anti-tgf-beta receptor ii antibodies

Also Published As

Publication number Publication date
AR130991A2 (es) 2025-02-05
JP7633259B2 (ja) 2025-02-19
MX2024002182A (es) 2024-05-03
AR120914A1 (es) 2022-03-30
JP2025083342A (ja) 2025-05-30
KR20220117267A (ko) 2022-08-23
AU2023200779A1 (en) 2023-03-09
AU2023200779B2 (en) 2026-02-19
IL304317A (en) 2023-09-01
CN116199780A (zh) 2023-06-02
IL294181A (en) 2022-08-01
EP4081306A1 (en) 2022-11-02
US20250270331A1 (en) 2025-08-28
JP2023508202A (ja) 2023-03-01
WO2021133167A1 (en) 2021-07-01
EP4269433A3 (en) 2024-05-22
TW202417513A (zh) 2024-05-01
US12570747B2 (en) 2026-03-10
BR112022012522A2 (pt) 2022-09-06
AU2026203807A1 (en) 2026-06-04
CA3165605A1 (en) 2021-07-01
MX2022007919A (es) 2022-07-27
JP7875406B2 (ja) 2026-06-18
EP4269433A2 (en) 2023-11-01
PH12022551527A1 (en) 2024-01-29
CN115038497A (zh) 2022-09-09
KR20230145542A (ko) 2023-10-17
TW202128747A (zh) 2021-08-01
AU2026203599A1 (en) 2026-05-28
AU2020412201A1 (en) 2022-07-14
JP2023076596A (ja) 2023-06-01
CN116375869A (zh) 2023-07-04

Similar Documents

Publication Publication Date Title
US20200377597A1 (en) Anti-pd-1 monoclonal antibody, and preparation method therefor and application thereof
JP7554309B2 (ja) 抗ｃｄ１４７抗体
EP4378954A1 (en) Anti-pvrig/anti-tigit bispecific antibody and application
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
US12479911B2 (en) Humanized anti-VEGF antibody Fab fragment
AU2023200779B2 (en) TGF-beta-RII binding proteins
US20260116991A1 (en) Monoclonal antibody for specifically recognizing glypican-3, and application thereof
JP7352007B2 (ja) ヒト化抗ｖｅｇｆモノクローナル抗体
KR20210108972A (ko) 항페리오스틴 항체 및 이의 용도
CA3165605C (en) Tgf-beta-rii binding proteins
HK40094429A (en) Tgf-beta-rii binding proteins
EA051539B1 (ru) Белки, связывающие tgf-бета-rii
BR122023027661A2 (pt) Proteínas de ligação de tgf-beta-rii
HK40066221B (en) Humanized anti-vegf fab antibody fragment and use thereof
HK40066221A (en) Humanized anti-vegf fab antibody fragment and use thereof
WO2025228351A1 (zh) 抗体，抗体药物偶联物及其用途
TW202436350A (zh) 抗ｌｉｌｒｂ１及／或抗ｌｉｌｒｂ２抗體及其等用途
HK40066231A (en) Humanized anti-vegf monoclonal antibody
HK40066231B (en) Humanized anti-vegf monoclonal antibody
BR112021003089A2 (pt) anticorpos biespecíficos anti-pd-l1/anti-lag3 e seus usos

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ THROSBY, MARK; KLOOSTER, RINSE AND DE KRUIF, CORNELIUS ADRIAAN

HB Alteration of name in register

Owner name: MERUS B.V.

Free format text: FORMER NAME(S): MERUS N.V.

FGA Letters patent sealed or granted (standard patent)